摘要 |
The invention relates to a therapeutic composition which contains as an active ingredient, a pharmaceutical, particularly 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and is applied in combination with one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or R-ICE and R-DHAP, which is a rituximab-containing combination regimen. The composition of the invention is useful for treatment of all solid cancers and lymphomas, preferably skin cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, prostate cancer, lung cancer, colon cancer, pancreatic cancer, renal cancer, stomach cancer and the like. In particular it is expected as a therapeutic agent for cancer resistant to other anticancer agents. |